Jiayi Wu

Jiayi Wu

Auto-generated profile, based on publicly available information

Jiayi Wu

Department of Breast Medical Oncology Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) Hangzhou China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2024 in Cancer
Verified
Journal Article
Open access
JWJiayi Wu
Jiayi Wu
WWWei Wang
Wei Wang
LGLu Gao
Lu Gao
XSXiying Shao
Xiying Shao
XWXiaojia Wang
Xiaojia Wang
Background: Clinical studies on programmed death‐ligand 1 (PD‐L1) immune checkpoint inhibitors for treating triple‐negative breast cancer (TNBC) have shown unsatisfactory efficacy due to low tumor‐infiltrating lymphocyte (TIL) levels. Inhibitors targeting cyclin‐dependent kinase (CDK) proteins can affect the immune microenvironment, increase TIL levels, and promote antitumor immunity, thus providing a new direction for TNBC treatment strategies.Methods: The authors tested three CDK inhibitors on the TNBC cell lines MDA‐MB‐231 and 4T1 and validated their antitumor effects and impact on the immune microenvironment using multiple detection methods. They verified the efficacy and immune‐related mechanisms of different combination therapy experiments in a 4T1 cell‐transplanted BALB/c mouse model.Results: Treatment with CDK inhibitors for 72 hours inhibited cell proliferation, clone formation, migration, and cell‐cycle arrest and induced apoptosis in human breast cancer MDA‐MB‐231 cells and mouse breast cancer 4T1 cells. CDK inhibitors suppressed DNA methylation by downregulating DNMT1, DNMT3a, and DNMT3b expression. These three inhibitors promoted the secretion of various chemokines, enhanced tumor cell antigen presentation, and increased PD‐L1 expression. CDK inhibitors improved the efficacy of immunotherapy in animal models and increased TIL levels.Conclusions: Combination therapy with CDK and PD‐L1 immune checkpoint inhibitors affects the immune microenvironment, promotes antitumor immunity, and improves the efficacy of immunotherapy for TNBC.

3 April 2024 in Clinical Case Reports
Verified
Journal Article
Open access
XSXia‐Bo Shen
Xia‐Bo Shen
JWJia‐Yi Wu
Jia‐Yi Wu
JLJia‐Ying Li
Jia‐Ying Li
XSXiying Shao
Xiying Shao
XWXiaojia Wang
Xiaojia Wang
Key Clinical Message: In a patient with metastatic breast cancer, an acquired BRCA mutation in the BRCA gene was detected, resulting in benefits from olaparib treatment. This underscores the importance of ongoing genetic phenotype testing after paclitaxel chemotherapy. Triple‐negative breast cancer (TNBC) is associated with a poor prognosis and elevated mortality risk. BRCA mutations are commonly regarded as prevalent mutations in TNBC patients, strongly associated with congenital familial heredity. Dynamic changes in mutation sites, however, are rarely reported. In this case report, we report a 59‐year‐old TNBC patient who developed pulmonary metastases post‐chemoradiotherapy. No BRCA mutations were detected through NGS. After 7.6 months of nab‐paclitaxel treatment, the patient experienced progression of lung metastases, and BRCA mutations were detected through NGS testing. Subsequent administration of olaparib resulted in a reduction in lung metastasis, demonstrating significant therapeutic efficacy. This case underscores the infrequent occurrence of treatment‐induced BRCA mutations and emphasizes the significance of dynamic NGS genetic testing for real‐time assessment of a patient's mutational status.